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ABSTRACT
Purpose To establish in vitro and in silico models that predict
clinical drug–drug interactions (DDIs) with the OATP1B1
(SLCO1B1) transporter.
Methods The inhibitory effect of 146 drugs and drug-like
compounds on OATP1B1-mediated transport was studied in
HEK293 cells. A computational model was developed to
predict OATP1B1 inhibition. Concentration-dependent effects
were investigated for six compounds; clinical DDIs were
predicted by calculating change in exposure (i.e. R-values) in
eight different ways.
Results Sixty-five compounds were identified as OATP1B1
inhibitors at 20 μM. The computational model predicted the
test set with 80% accuracy for inhibitors and 91% for non-
inhibitors. In vitro–in vivo comparisons underscored the
importance of using drugs with known clinical effects as
references. Thus, reference drugs, cyclosporin A, gemfibrozil,
and fenofibrate, provided an inhibition interval to which three
antiviral drugs, atazanavir, lopinavir, and amprenavir, could be
compared and their clinical DDIs with OATP1B1 classified.
Conclusions Twenty-two new OATP1B1 inhibitors were
identified, a predictive OATP1B1 inhibition in silico model was
developed, and successful predictions of clinical DDIs were
obtained with OATP1B1.
KEY WORDS in silico.in vitro–in vivo extrapolation.
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ABBREVIATIONS
ABC ATP-binding cassette
AUC area under the plasma-concentration time
curve
BCRP breast cancer resistance protein
DDI drug–drug interaction
E17βG estradiol-17β-glucuronide
E3S estrone-3-sulphate
ESI electrospray ionization
Fa fraction absorbed
FBS fetal bovine serum
Fu fraction unbound
HBSS Hank’s balanced salt solution
HEK293 human embryonic kidney 293 cells
HMG-CoA 3-hydroxy-3-methylglutaryl-coenzyme A
Iin,max maximal inhibitor concentration at the inlet
of the liver
Imax maximal systemic plasma concentration of
the inhibitor
ka absorption constant
MDR1 multi-drug resistance protein 1
MQ Milli-Q
MRP multi-drug resistance associated protein
NTCP Na
+-taurocholate co-transporting polypeptide
OATP organic anion transporting polypeptide
OPLS-DA orthogonal partial least squares projection to
latent structures discriminant analysis
PCR polymerase chain reaction
Pgp P-glycoprotein
Qh hepatic blood flow
SLC solute carrier
UPLC-MS/MS ultra performance liquid chromatography-
tandem mass spectrometry
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The liver-specific organic anion transporting polypeptide
1B1, OATP1B1 (SLCO1B1), is one of the highest expressed
uptake transporters in the human hepatocyte (1,2). It is
localized in the basolateral membrane of the hepatocyte
and translocates substrates from the bloodstream into the
hepatocyte. The significance of OATP1B1 has recently been
emphasized by its inclusion as one of seven transporters of
considerable importance for drug disposition (3). In that
paper,authoredbytheInternationalTransporterConsortium,
criteria for the identification of important elimination routes
are given, along with predictive decision trees and suggestions
for the extrapolation of the in vitro OATP1B1 results to
the in vivo situation. OATP1B1 has previously been shown
to interact predominantly with negatively charged compounds
(4,5) and is known to transport a number of drugs, e.g. 3-
hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) inhibitors
(statins), bosentan and repaglinide (6–8). In addition, it
mediates the transport of several endogenous compounds,
such as bile acids, in parallel with, e.g., the bile acid transporter
Na
+-taurocholate co-transporting polypeptide (NTCP,
SLC10A1)( 9,10). In concert with the efflux transporter multi-
drug resistance associated protein 2 (MRP2, ABCC2), which is
positioned in the apical membrane of the hepatocyte, it has
been suggested that OATP1B1 is involved in active vectorial
transport of compounds from the blood to the bile (11).
Several drugs inhibit OATP1B1-mediated transport,
which may result in lower hepatic intracellular and higher
blood concentrations of OATP1B1 substrates (2,12,13).
The importance of OATP1B1 in drug transport is under-
lined by its involvement in drug–drug interactions (DDIs)
described throughout the literature (6,7,14). For instance,
the area under the curve (AUC) of the OATP1B1 substrate
rosuvastatin was increased 7.1 times when co-administered
with the OATP1B1 inhibitor cyclosporin A (14). In vitro
models suggested that the observed increase in the AUC
was related to the inhibition of OATP1B1 (14). Similarly,
DDIs with OATP1B1 have been shown for rifampicin and
botensan (8,15), and OATP1B1 may also be involved in the
reported DDIs of gemfibrozil and a number of statins (7).
The observations of DDIs at the OATP1B1 level have
called for reliable and easy-to-use models to make it possible to
identify such DDIs already in the pre-clinical stage. Indeed, a
number of experimental in vitro models have been used with
some success to investigate inhibition of the OATP1B1
transporter (13,14,16). In addition, tools combining in vitro
and in silico models for the potential identification of DDIs in
the early phases of the drug discovery process have been
described (17). However, as yet, no extensive systematic study
has been conducted on drug–drug interactions with OATP1B1.
Previously, we developed experimental and computational
models for efflux (multi-drug resistance protein 1 (MDR1 or
Pgp, ABCB1), breast cancer resistance protein (BCRP,
ABCG2) and MRP2) and uptake (organic cation transporter
1 (OCT1, SLC22A1)) transporters (18–21), all of which are of
considerable importance for hepatic drug transport and
clearance. For these transporters, optimized in vitro methods
were developed, and experimental data for large datasets of
compounds were generated to aid in the development of
predictive in silico models. Here, we describe an in vitro
screening assay for the rapid assessment of OATP1B1
inhibition and then present an application of this assay
to the investigation of the inhibition potential of 146
drugs and drug-like compounds. We then use the
experimental data to develop a computational model for
the prediction of OATP1B1 interactions. Finally, we make
in vitro–in vivo extrapolations by calculating the so-called
R-values (i.e. the predicted change in exposure of a drug)
using recently published procedures (3,22) and predicted
clinical DDIs involving OATP1B1 for a dataset of six
compounds using the specific substrate atorvastatin. Our
results emphasize the DDI potential of OATP1B1 and
add to the existing evidence supporting the usefulness of
rather simple in vitro and in silico tools for the identification
of DDIs with transport proteins.
MATERIALS AND METHODS
Compounds
A dataset of 146 compounds was used for the investigation. A
list of suitable candidates was compiled from a model dataset
for transporter interaction studies (21), and this list was
extended with compounds known to interact with OATP1B1
and/or MRP2 (21), bile acids and three therapeutic groups
of interest for OATP1B1: statins, protease inhibitors and
anti-diabetic compounds. The substances were obtained
fromSigma-Aldrich(St.Louis,MO),InternationalLaboratory
USA(SanBruno, CA),3BScientificCorporation(Libertyville,
IL) and AstraZeneca R&D Mölndal (Sweden). Radiolabeled
estradiol-17β-glucuronide (E17βG) was obtained from
PerkinElmer (Waltham, MA).
Construction of an OATP1B1 Expression Vector
The SLCO1B1/OATP1B1 open reading frame was
obtained using restriction digestion with KpnI/XhoI from
an SLCO1B1/OATP1B1-pcDNA3.1 expression vector
(kindly provided by Dr Lena Gustavsson, AstraZeneca
R&D Lund, Sweden). The resulting DNA fragment was
cloned into the corresponding restriction sites of the expres-
sion vector pcDNA5/FRT (Invitrogen, Carlsbad, CA). The
inserted sequence was verified by DNA sequencing analysis
(Uppsala Genome Center, Uppsala, Sweden).
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Human embryonic kidney cells Flp-In-293 (Invitrogen,
Carlsbad, CA) were transfected with the pOG44 vector
(Invitrogen, Carlsbad, CA) and with the constructed
OATP1B1-pcDNA5/FRT expression vector or empty
pcDNA5/FRT vector (mock) using Lipofectamine 2000
(Invitrogen, Carlsbad, CA) according to the manufacturer’s
recommendations. Stable clones were obtained by selection
using Flp-In-293 medium (Dulbeccos’s modified eagle’s
medium supplemented with 10% fetal bovine serum (FBS)
and 2 mM L-glutamate) supplemented with 75 μg/ml of
Hygromycin B (Invitrogen, Carlsbad, CA). For continued
culturing, the stable clones were cultivated in Hygromycin B
supplemented Flp-In-293 medium.
All cells were cultured at 37°C in an atmosphere of 95%
air and 5% CO2 and sub-cultured twice a week. Passage
numbers 5 to 30 were used throughout the study. All cell
culture media and reagents were obtained from Invitrogen
(Carlsbad, CA) or Sigma-Aldrich (St.Louis, MO).
T w ot o3d a y sp r i o rt op e r f o r m i n gt h et r a n s p o r t
experiments, cells were seeded in black 96-well poly-D-
lysine coated plates (Greiner, Frickenhausen, Germany) or
CellBind plates (Corning, Amsterdam, Netherlands)
(experiments using E17βG as substrate), or 24-well Cell-
Bind plates (Corning, Amsterdam, Netherlands) (experi-
ments conducted using atorvastatin as the substrate) at a
density of 30,000–60,000 (96-well plates) or 600,000 cells/
well (24-well plates). The cell density was optimized using
computer-assisted experimental design conducted with
MODDE 7.0 (Umetrics, Umeå, Sweden) as described
below.
Transport and Inhibition Studies
Inthetransportstudies,describedbelow,allexperimentswere
performed in at least triplicate. Common to all experimental
protocols was the following procedure: before starting the
experiment, cells were washed twice with pre-warmed HBSS
withpH7.4,followedbyincubationat37°Cwithpre-warmed
test solutions. The transport experiments were terminated by
adding ice-cold buffer, followed by four washing steps. Total
protein content was measured using the BCA Protein Assay
Reagent Kit (Pierce Biotechnology, Rockford, IL) according
to the manufacturer’s instructions. In all experiments, mock-
transfected cells were included on each plate to correct for the
passive permeability.
Characterization of the OATP1B1 Transport
The cells grown in the 96-well plates were incubated
with a solution containing 1 μCi/ml (24 nM)
3H-
estradiol-17β-glucuronide (
3H-E17βG) and 1–200 μMo f
unlabeled E17βGi nH B S S ,a n dt h e na n a l y z e du s i n ga
liquid scintillation counter as described below to deter-
mine Km and Vmax of the model substrate E17βG, which
was used as a substrate in single point inhibition experi-
ments. The Km and Vmax of atorvastatin, the specific
substrate used in the in vitro–in vivo extrapolation experi-
ments, were determined using cells grown in 24-well
plates. The cells were incubated with a solution containing
0.2–50 μM atorvastatin in HBSS and analyzed using
UPLC-MS/MS as described below. Uptake kinetics were
assessed by plotting the initial uptake rate (uptake after
1 min) against the substrate concentration [S]; apparent
Km and Vmax were determined by non-linear regression
(using Prism v.4.02 from GraphPad, San Diego, CA) fitted
to Eq. 1:
v ¼
Vmax½S 
K M þ½ S 
þ Pdif  ½ S ð 1Þ
where Pdif is the passive permeability of the substrate.
Substrate concentrations well below or close to the Km were
selected for future studies using E17βG or atorvastatin,
respectively.
Screening for Inhibition of OATP1B1-Mediated Transport
Screening for inhibition of OATP1B1-mediated transport
was achieved by performing single point inhibition meas-
urements. Experimental design, as implemented in
MODDE 7.0 (Umetrics, Umeå, Sweden), was used for
optimizing the assay with regard to the substrate concen-
tration, amount of labeled substrate, incubation method,
cell seeding density, and number of days in culture before
the experiments (18). Within the experimental design, the
results from the OATP1B1 transport characterization were
considered for the optimization of the substrate concentra-
tion and incubation time. In summary, in the screening
assay, cells that were grown in 96-well plates were
incubated for 5 min with a solution containing 20 μMo f
the test compound, 1 μCi/ml (24 nM)
3H-E17βG and
0.5 μM E17βG in HBSS. The strong inhibitor estrone-3-
sulphate (E3S) was included on each plate as a control.
OATP1B1 cells incubated without a potential inhibitor
were used as the reference for the calculations of the
inhibitory percentage of the compounds under investiga-
tion. A compound was classified as an OATP1B1 inhibitor
if it inhibited the uptake of E17βG by more than 50%
(18,21).
Establishment of IC50 Curves
Cells grown in 24-well plates were incubated for 2 min with
a test solution containing 1 μM atorvastatin to enable
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OATP1B1 inhibitors and non-inhibitors: cyclosporin A
(0.01–25 μM), gemfibrozil (0.01–500 μM), fenofibrate (0.1–
100 μM), atazanavir (0.01–100 μM), amprenavir (0.01–
500 μM) or lopinavir (0.01–10 μM). The intracellular
atorvastatin content was analyzed using UPLC-MS/MS as
described below. The passive uptake in mock cells was
subtracted from the total uptake in the OATP1B1 express-
ing cells at each inhibitor concentration. IC50 was deter-
mined and the apparent Ki (assuming the kinetics
appropriate for competitive inhibition) calculated using
Prism version 4.02 (GraphPad, San Diego, CA).
Liquid Scintillation Analysis
Immediately after the final washing steps in the transport
experiments, the cells incubated with radioactive E17βG
were trypsinized, lysed using 1 M NaOH, and then
neutralized using 1 M HCl. Thereafter, the intracellular
concentrations were analyzed with an Ultima Gold scintil-
lation cocktail (PerkinElmer, Shelton, CT) using a Beckman
LS6000IC liquid scintillation counter (Beckman Coulter,
Fullerton, CA).
UPLC-MS/MS Analysis
After the final washing steps, the cells incubated with
atorvastatin were dried, and extracted using 0.2 mL AcN:
H2O 60:40 spiked with 50 nM warfarin as the internal
standard, which was followed by centrifugation at 3,500 rpm
for 20 min using a 5810R centrifuge from Eppendorf
(Hamburg, Germany). Thereafter, the supernatants were
subjectedtoUPLC-MS/MS analysisofintracellularatorvastin
concentrations using the following analytical system: UPLC
(Waters, Milford, MA) coupled to a Thermo Quantum
DiscoverytriplequadrupolewithESIinterface,withareversed
phase C18 column (particle size of 1.7 μm) (Waters, Milford,
MA) and a mobile gradient consisting of acetonitrile, formic
acid and MQ-water.
Calculation of R-Values and In Vitro to In Vivo
Drug–Drug Interaction Predictions
For the five selected compounds (including three
inhibitors and two non-inhibitors in vivo)w h e r ea nI C 50
and Ki value could be obtained, an in vitro–in vivo
extrapolation was conducted by calculating the changes
in drug exposure, i.e. the R-values, with or without these
five selected compounds, through the use of both Eqs. 2
and 3:
R ¼ 1 þ
Fu»Iin;max
IC50
ð2Þ
R ¼ 1 þ
Fu»Iin;max
K i
ð3Þ
in which Fu is the fraction unbound, obtained from the
maximal inhibitor concentration at the inlet of the liver,
Iin,max, which was calculated using Eq. 4 (3,22):
Iin;max ¼ Imax þ
Fa»Dose»ka
Q h
ð4Þ
where Fa isthefractionabsorbed(equalheretothemaximum
reported oral bioavailability (23–25), or set to 1 for the
purpose of comparison with previous in vitro–in vivo extrap-
olations (3)). For lopinavir, no data could be identified for the
bioavailability, so only a value of Fa=1 could be used. The
dose is the maximum oral dose given, Imax is the maximal
systemic plasma concentration (obtained from (24–28)), ka is
the absorption constant (here, set to 0.03 or 0.1 (22,29)), and
Qh is the hepatic blood flow (1.5 l/min (3)). Equation 3,
using Ki for R-extrapolation, was used by Hirano and co-
workers in a paper from 2006 (22), in which the authors
recommended setting the Fa equal to 1 and using a value of
ka=0.1 to estimate the maximum Iin,max. In contrast, the
recent paper from the International Transporter Consortium
uses Eq. 2,I C 50 and ka=0.03 for the R-extrapolation (3). In
the latter publication, no recommendation is made regarding
Fa, although Fa=1 is used for the examples provided by the
authors. Using these approaches and equations, as well as
combining different values for the fraction absorbed (Fa)a n d
the absorption rate constant (ka), as indicated above, a total of
eight R-values were obtained for each compound. A mean
R-value was calculated for each compound for use in
comparisons with clinical data.
Molecular Descriptors
Three-dimensional molecular structures were generated
from SMILES representations using Corina, version 3.0
(Molecular Networks, Erlangen, Germany), and were used
as the input for molecular descriptor calculations per-
formed with DragonX, version 1.4 (Talete, Milan, Italy),
ADMETPredictor, version 5.0 (SimulationsPlus, Lancaster,
CA), and SELMA (AstraZeneca R&D, Mölndal, Sweden).
A totalof91moleculardescriptors representing the molecular
size, flexibility, connectivity, polarity, and hydrogen bonding
potential,allofwhichhadpreviouslybeenusedforpredictions
of transport protein interactions (20,21), were used in the
computational modeling procedure.
Computational Modeling
Every third compound when the compounds were listed
alphabetically was included in the test set and kept out of
the model development. The remaining compounds were
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multivariate discriminant analysis was performed to separate
inhibitors from non-inhibitors and to identify the critical
molecular properties causing transporter inhibition. The two
resulting datasets consisted of 98 compounds (including 44
inhibitors) in the training set and 48 compounds (of which 21
were inhibitors) in the test set. This resulted in a test set that
was well covered by the training set used with regard to
inhibitory effect and chemical structure, as shown by a
principal component analysis using SIMCA-P+ version 11.0
(Umetrics, Sweden). However, in the five first principal
componentsofthePCA ofthechemicalspace,which together
described 78% of the chemical variation of the dataset,
bromosulfalein,cholecystokininoctapeptideandlevothyroxine
were identified as outliers. These compounds were, therefore,
excluded from the training set to avoid biasing the model.
Orthogonal partial least squares projection to latent structures,
discriminant analysis (OPLS-DA), as implemented by
SIMCA-P+ version 11.0, was used to obtain computational
models for the separation of OATP1B1 inhibitors from non-
inhibitors. Inhibitorswere giventhe value 1 andnon-inhibitors
the value −1. The descriptors generated by DragonX were
used as the input for the computational modeling. Charge was
not included as a descriptor, since the charge descriptor,
generated by different software, will be largely dependent on
the accuracy of the pKa prediction, a property for which the
predictions vary greatly from software to software. Instead, we
took the simple approach of using only generally available
DragonX descriptors (that do not cover charge descriptors) as
the input for the model. A variable selection procedure was
used in which groups of molecular descriptors that did not
contain information relevant to the problem (i.e. noise) or
which overlapped with other descriptors in their information
content (as identified through proximity in the OPLS loading
plots of the resulting models) were removed in a stepwise
manner to optimize the model performance and to ensure that
the final model would be transparent. If the molecular
descriptors remaining in the model resulted in a prediction
>0, the compound was classified as an inhibitor, whereas a
negative value predicted the compound to be a non-inhibitor
ofOATP1B1. Weexcludeddescriptorsfromthe modeliftheir
removal resulted in improved or unaltered discrimination
between inhibitors and non-inhibitors in the training set.
RESULTS
Characteristics of the Dataset
The dataset investigated is within the chemical space for
prescribed oral drugs. Inclusion of compounds already
known to interact with OATP1B1 and compounds with
related structures to known inhibitors skewed the charge
distribution of the dataset towards anionic drugs. This was
deliberate, as it was intended to enrich the dataset with
compounds likely to interact with OATP1B1. The range of
the molecular weight of the compounds was from 108.1
(quinone) to 1202.8 (cyclosporin A), with a mean value of
428.0 (±140.4) g/mol (Fig. 1a). This is higher than the
mean value of 343.7 g/mol for marketed low-molecular-
weight drugs (30). Further, as shown in Fig. 1b,t h e
lipophilicity (logP) of the dataset ranged between −7.0
(acarbose) and 7.4 (tipranavir), with a mean value of 2.90
(±1.65). The topological polar surface area ranged between
3.2 (amitriptyline) and 434.0Å
2 (cholecystokinin octapep-
tide (CCK-8)) with a mean of 106.9Å
2 (±52.5), as displayed
in Fig. 1c. The mean lipophilicity and polar surface area in
the dataset were similar to the mean values reported for
registered oral drugs. Thirty-two percentages of the com-
pounds were neutral, 39% were anions and 25% were
cations (Fig. 1d) at pH 7.4.
Establishment of OATP1B1 Cell Models
The deduced amino acid sequence for the SLCO1B1/
OATP1B1-pcDNA5/FRT construct was found to be
identical with the OATP1B1 wild-type variant, i.e. the
SLCO1B1*1a allele. Real-time PCR and Western blot
analyses showed that the OATP1B1 mRNA and protein
were specifically expressed in the OATP1B1 transfected
cells and that the OATP1B1 protein was localized at the
plasma membrane (data not shown).
Estradiol-17β-Glucuronide and Atorvastatin
Transport Kinetics
The uptake of E17βG was linear over the first 10 min, and
the uptake of atorvastatin was linear for 2 min (data not
shown). All uptake experiments were performed in the
linear interval, with the chosen durations being 5 min and
2 min for E17βG and atorvastatin, respectively. At the end
of these periods, the uptake of E17βG and atorvastatin in
the OATP1B1 cells was at least 8 and 3 times higher than
the values obtained in mock-transfected cells, respectively.
OATP1B1-expressingcellsexhibitedaKm for E17βG of 12.85
(± 2.40) μMa n daV max of 1.37 (± 0.12) pmol/min/mg
protein (Fig. 2a). For atorvastatin, a Km of 0.77 (± 0.24) μM
and a Vmax of 6.61 (± 1.24) pmol/min/μg protein were
obtained (Fig. 2b).
OATP1B1 Interaction and Characteristics
of the Inhibitors
In the interaction studies, 65 of the 146 compounds
analyzed (44.5%) inhibited the transport of E17βGb y
50% or more at 20 μM and were therefore classified as
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identified, as many as 22 were identified that had not been
reported to interact with OATP1B1 previously. These
included 5-CFDA, adefovir, candesartan, diclofenac, dieth-
ylstilbestrol, dipyridamole, GF120918, glycochenodeoxy-
cholate, glycodeoxycholate, indomethacin, ivermectin,
nicardipine, N-methylnicotinamide, nystatin, quinine, re-
serpine, spironolactone, sulfasalazine, taurochenodeoxycho-
late, taurodeoxycholate, tipranavir and vinblastine. The
inhibitors identified were larger than the non-inhibitors, as
shown by the difference in the mean molecular weight of
the inhibitors (528.0±151.4 g/mol) and non-inhibitors
(347.8±103.4 g/mol) (Fig. 3b). Fifty-eight percent of the
inhibitors carried a negative charge at pH 7.4, in contrast
to only four positively charged inhibitors (6%): GF120918,
quinine, erythromycin and rosiglitazone (Fig. 3c). This
enrichment of negatively charged compounds among the
inhibitors and the presence of only low numbers of
positively charged OATP1B1 inhibitors are significantly
different from the charge distribution seen for all 146
compounds analyzed. Three known OATP1B1 substrates
were not identified as inhibitors in our assay: penicillin G,
phalloidin, and levothyroxin (31–33). When investigated at
higher concentrations (75 and 100 μM), an increased
inhibition of E17βG uptake was observed for all three
compounds (data not shown). At both 75 and 100 μM,
levothyroxin would actually be classified as an inhibitor (i.e.
>50% inhibition). Phalloidin, on the other hand, is a
borderline compound, only reaching 49% inhibition
(±13%) at a concentration of 100 μM, whereas even at
100 μM, penicillin G is classified as a non-inhibitor only
inhibiting OATP1B1 to 32 (±18)%.
All statins (n=8) and protease inhibitors (n=7) inhibited
OATP1B1 to more than 50% (Table I), whereas seven of
the eight bile acids and three of the nine anti-diabetic
compounds examined (rosiglitazone, repaglinide, glibencla-
mide) were classified as OATP1B1 inhibitors at 20 μM
(Table I). The latter is in accordance with previous in vitro
and in vivo studies identifying rosiglitazone, repaglinide, and
glibenclamide as inhibitors and metformin and tolbutamide
as non-inhibitors (22,34,35).
A substrate overlap has been suggested for OATP1B1
and the ABC transporter MRP2, (ABCC2)( 11), but a
corresponding overlap between OATP1B1 and MRP2
Fig. 1 The frequency distribution of the molecular properties of the dataset investigated for OATP1B1 inhibition. The distribution of molecular weight (a),
AlogP (lipophilicity) (b), polar surface area (PSA) (c) and compound net charge at physiological pH (d) for the investigated compounds in the dataset.
416 Karlgren et al.inhibitors could not be observed for the 42 compounds in
this study that were previously identified as inhibitors of the
MRP2 transporter (21).
In Silico Prediction of OATP1B1 Inhibitors
A computational model in which inhibitors were discrim-
inated from non-inhibitors was developed. The final model,
after optimization through variable selection, was a single
principal component OPLS-DA based on four descriptors,
reflecting compound lipophilicity, polarity, size, and shape
(Fig. 4a). The model shows that the inhibitors tend to be
more lipophilic (AlogP descriptor), be larger (Mw descrip-
tor) and display a larger polar surface area (PSA) than the
non-inhibitors. In addition, the inhibitors display a lower
value of the less interpretable shape descriptor, the Mean
Square Distance Index (MSD), which is a topological
distance descriptor normalized for size (36).
The OPLS-DA model successfully classified 81% of the
inhibitors and 93% of the non-inhibitors in the test set
(n=48) (Fig. 4b), indicating good applicability of the
model. Transforming the OPLS-DA results to a multi-linear
equation for the prediction of OATP1B1 inhibition resulted
in OATP1B1 inhibitors being identified if the following sum
results in a positive value:
OATP1B1inhib ¼  0:167 þ 0:001Mw   3:234MSD
þ 0:062AlogP þ 0:002PSA ð5Þ
Hence, negative values (<0) as output from Eq. 5 predict
the compound to be a non-inhibitor of OATP1B1.
Concentration-Dependent Inhibition of Atorvastatin
Uptake
For six selected OATP1B1 inhibitors and non-inhibitors,
inhibition curves were derived using atorvastatin as the
victim drug. As expected, inhibition curves could be
derived and IC50 and Ki-values calculated for the five
compounds previously classified as inhibitors in the
screening assay (cyclosporin A, gemfibrozil, lopinavir,
atazanavir, amprenavir). Fenofibrate did not inhibit
atorvastatin uptake in the investigated concentration
i n t e r v a l ;h e n c e ,n oI C 50-o rK i-values were calculated.
For the three compounds used later on as calibrators in
the in vivo predictions (see below), the expected inhibition
ranking was obtained: cyclosporin A≫gemfibrozil≫fenofi-
brate. IC50-values obtained were 1.88 μM for cyclosporin
Aa n d1 5 6 . 2μMf o rg e m f i b r o z i l ,a n dK i-values were
0.82 μMa n d6 8 . 0 5μM for cyclosporin A and gemfibrozil,
respectively (Fig. 5,T a b l eII)( 37). For the remaining three
HIV protease inhibitors, a concentration-dependent inhi-
bition of atorvastatin uptake was observed, where lopina-
vir>atazanavir>amprenavir. The IC50 ranged between
0.74 μM (lopinavir) and 16.80 μM (amprenavir) and the Ki
between 0.32 μM (lopinavir) and 9.52 μM (amprenavir)
(Fig. 5,T a b l eII).
Prediction of In Vivo Interactions
Recently, in vitro–in vivo extrapolation methods were
proposed for prediction of clinical drug-drug interactions
with drug-transporting proteins (3,22). These predictions
are based on experimentally determined IC50-a n dK i-
values, such as those presented for OATP1B1 in Table II
and Fig. 5, and from which changes in drug exposure (R)
are calculated as described in the methods section. Several
variants for calculation of R-values have been proposed,
w h e r ee i t h e rI C 50 or Ki values are used, and where
different values are given to constants such as Fa and ka in
Eq. 4.
In the following, we investigate if calculated R-values
could be used to predict previously observed clinical drug–
Fig. 2 Michaelis-Menten kinetics of uptake in HEK293 cells stably
expressing the OATP1B1 transporter. Cells grown in 96-well plates were
incubated with 1–200 μM estradiol-17β-glucuronide (E17βG) and 1 μCi/
ml of
3H-E17βG at 37°C. The intracellular accumulation of
3H-E17βG
was measured using a scintillation counter and the results presented here
as the uptake in pmol per minute and per mg total protein (a). Each data
point represents the mean uptake ± standard deviation (n=3). Cells
grown in 24-well plates were incubated with 0.2–5 μM atorvastatin at 37°
C. The intracellular accumulation of atorvastatin was measured using
UPLC-MS/MS analysis and results presented here as the uptake in pmol
per minute and per μg total protein (b). Each data point represents the
mean uptake ± standard deviation (n=2).
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examined for atorvastatin inhibition in our study (Fig. 5,
Table II). We also calculate R-values in eight different ways
in order to investigate if any of the calculation methods
provide better in vitro–in vivo predictions. For this purpose,
we included three calibrators—cyclosporin A (a strong
inhibitor), gemfibrozil (a moderate inhibitor) and fenofibate
(a non-inhibitor)—to cover the range of the reported
changes in the AUC in vivo. Using the maximal inhibitor
concentration at the inlet of the liver (Iin,max) (obtained from
Eq. 4 and variables shown in Table III), the predicted
change in exposure (R) was calculated using Eqs. 2 and 3.
As can be seen in Table IV, the R-values varied depending
on whether Eq. 2 (using IC50) or Eq. 3 (using Ki) was used
and on which values of Fa (the reported compound-specific
value or assumed complete absorption) and ka (0.03 or 0.1)
were used in the calculations (Fig. 6, Tables III, IV). The
mean R-value obtained for the strong OATP1B1 inhibitor
cyclosporin A was 3.21 (range 1.46–7.15) and for the
moderate inhibitor gemfibrozil was 1.11 (range 1.05–1.19)
(Table IV, Fig. 7). The mean R-values for the three test
compounds were as follows: lopinavir, 2.91 (range 1.76–
4.58); atazanavir, 4.02 (range 2.06–7.49); and amprenavir
1.49 (range 1.19–1.95) (for all R-values as well as the
Fig. 3 Percentage inhibition of the dataset, as well as the compounds’ properties of the OATP1B1 inhibitors identified. The mean percentage inhibition
(± standard deviation) of all 146 of the compounds investigated (a). The 50% cut-off level is indicated by the dashed line. The inhibitors (black squares)
and non-inhibitors (grey dots) superimposed on the oral drug space, presented as a PCA score plot (b). The first principal component (x-axis in the plot) is
largely governed by the molecular size, which increases to the right. The second principal component (y-axis) is largely governed by the lipophilicity, which
increases downwards. PC1 and PC2 describe 56% of the chemical variation of the oral drug space. The charge distribution of the inhibitors identified (c).
418 Karlgren et al.corresponding letter used, see Table IV). Of the eight
different R-values calculated, the most pronounced differ-
ence between the groups of non-inhibitors and inhibitors
was observed for R-value H with a 6.3-fold difference
between the highest and lowest inhibitor and non-inhibitor,
respectively (Fig. 6a). R-value H was calculated using the
method described by Hirano and co-workers (22); there,
Eq. 3 (based on a Ki-value) is used together with a default
value of ka equal to 0.1 an Fa equal to 1. In addition, for R-
value B (the R-calculation proposed by the International
Transporter Consortium (3)), an Fa equal to 1 is used.
However, the major differences when compared to the
Table I Inhibition of Estradiol-17β-glucuronide Uptake by the Compounds Investigated
Drug-Drug Interactions at the OATP1B1 Transporter 419Fig. 4 Performance of the in silico model. Accuracy of the prediction of OATP1B1 inhibition for the training and test sets (left and right panels,
respectively) (a). The OPLS-DA coefficients show that the molecular weight (Mw), polar surface area (PSA) and lipophilicity (AlogP) are positive for
OATP1B1 inhibition and that the mean square distance (MSD; a Balaban index descriptor) is negative for OATP1B1 inhibition (b).
Fig. 5 Inhibition of OATP1B1-mediated atorvastatin uptake in HEK293 cells stably expressing the OATP1B1 transporter for the three calibrators:
cyclosporin A, gemfibrozil, fenofibrate (a) and for the three protease inhibitors investigated: lopinavir, atazanavir, amprenavir (b). HEK293-OATP1B1 and
mock-transfected cells grown in 24-well plates were incubated with 1 μM atorvastatin together with increasing concentrations of the potential inhibitors for
2 min at 37°C. The intracellular accumulation of atorvastatin was measured using UPLC-MS/MS analysis. On the y-axis, the relative amount transportedi n
comparison to a non-inhibitor control is shown as a percentage ± standard deviation (n=4, for 200 and 500 μM amprenavir n=2). At each inhibitor
concentration, the passive uptake of atorvastatin in the mock cells was subtracted from the total atorvastatin uptake in the OATP1B1-expressing cells. On
the x-axis, the inhibitor concentration is shown as log μM. For fenofibrate, no curve could be generated, so only the values obtained are shown.
420 Karlgren et al.value is used instead of Ki, and a default value of ka equal
to 0.03 is used instead of 0.1. This results in lower R-values
than the ones obtained with the method described by
Hirano et al.( 22), with a 2.3-fold difference between the
highest and lowest calculated R-value, in comparison to a
6.3-fold difference for R-value H (Fig. 6).
DISCUSSION
In this paper, we investigated OATP1B1 inhibition for a
dataset of 146 compounds within the chemical space of oral
drugs and enriched with compounds considered likely to
interact with OATP1B1. Through this approach, a
relatively large number of inhibitors was identified (42%),
supporting the notion that OATP1B1 should be considered
in predictions of clinical drug–drug interactions (6,7,14,15),
charge (Fig. 3c)( 4,5).
Three compounds that have previously been reported to
interact with OATP1B1 (penicillin G, phalloidin, levothyr-
oxine (31–33)) were not identified as inhibitors according to
our definition (>50% inhibition at 20 μM). When investi-
gated at higher concentrations, an increased inhibition of
OATP1B1-mediated E17βG uptake was observed for all
three of the compounds. Hence, we conclude that although
these compounds were not defined as OATP1B1 inhibitors
in our study, they could be classified as inhibitors if a less
stringent definition is used.
Interestingly, among the 22 novel OATP1B1 inhibitors
identified in this study, we found compounds known to be
substrates or inhibitors foro t h e rt r a n s p o r t e r s ,e . g .
GF120918 and ivermectin, both of which are reported to
interact with MDR1 and also with other ABC transporters
(http://125.206.112.67/tp-search)( 20). One inhibitor,
diclofenac, was confirmed to be an OATP1B1 inhibitor
during the finalization of this manuscript by Kindla and co-
workers (16). In addition to the novel inhibitors that we
identified, we confirm the hypothesis that, e.g., indometh-
acin, spironolactone, tipranavir, taurochenodeoxycholate
and taurodeoxycholate interact with the OATP1B1 trans-
porter, as suggested by previous studies and investigations
using human hepatocytes. Tipranavir, which inhibited
OATP1B1 to approximately 90% here, had been suggested
to be an OATP1B1 inhibitor in an earlier in vivo study (38).
Both for tipranavir and for the other novel OATP1B1
inhibitors identified here, further investigation will be needed
to confirm our findings and to establish the importance of
OATP1B1 in DDIs in comparison to the relative importance
of other transporters and metabolizing enzymes involved in
the pharmacokinetics of these compounds.
We used our experimental data to analyze OATP1B1
inhibitors and non-inhibitors from a molecular perspective
using both single correlations between inhibition and
molecular properties and a multivariate data analysis. We
found that OATP1B1 inhibitors tend to be more lipophilic,
Table III Variables Used for the Calculation of R-Values
Imax
a (μM) Fa
b Dose
c (mg) Fu
d
Cyclosporin A 1.37 0.5 886.2 0.1
Gemfibrozil 99.9 0.98 600 0.05
Fenofibrate 29.8 0.81 300 0.01
Lopinavir 15.4 na 400 0.02
Atazanavir 4.47 0.68 400 0.14
Amprenavir
e 11.2 0.9 600 0.1
na not available
aMaximum systemic plasma concentration of the inhibitor, obtained from
(23–28)
bFraction of the inhibitor dose absorbed. Here, the maximum oral
bioavailability, as obtained from (23–25), is displayed
cInhibitor dose for each occasion on which a dose was given, obtained
from (23–28)
dFraction of the inhibitor that is unbound, obtained from (3,23,24)
eImax and the dose, recalculated from Fosamprenavir data
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calculation of R-value H are that for R-value B, the IC50- particularly if the drug is uncharged or has a negative
Table II IC50- and Ki-Values Obtained for the Six Compounds Investigated Using HEK293-OATP1B1 Cells and Atorvastatin as the Substrate, Relative
Changes in the AUC for Atorvastatin and Rosuvastatin (as Reviewed by Kalliokoski and Niemi (37) or Reported by (27,43,51))
IC50 (μM) Ki (μM) Fold AUC change
Atorvastatin
Fold AUC change
Rosuvastatin
Cyclosporin A 1.88 0.82 10.5 (7.4–15.3) 7.1
Gemfibrozil 156.2 68.05 1.2 1.9
Fenofibrate –– – 1.1
Lopinavir 0.74 0.32 – 2.1
Atazanavir 1.61 0.91 – 3.1
Amprenavir 16.80 9.52 – 1.1
a
aThe prodrug Fosamprenavir was used in the studybe larger, display a larger polar surface area, and be
enriched with regard to anionic charge in comparison to
non-inhibitors. Comparing the molecular properties defin-
ing OATP1B1 inhibitors in this study with those obtained
in investigations of other transport proteins reveals that
several molecular properties are shared between inhibitors
of different transport proteins. For instance, lipophilicity
seems to be a general property of transporter inhibitors
(18–21,39). The accuracy of the classification of inhibitors
and non-inhibitors obtained using the PLS-DA model
introduced here was similar to that of models developed
previously by our group for the OCT1, MRP2, MDR1 and
BCRP transporters (18–21). Through the use of these and
Table IV Calculated R-Values
Eq. 2 R ¼ 1 þ fu»Iin;max
IC50 Eq. 3 R ¼ 1 þ fu»Iin;max
Ki Average
ka=0.03
a ka=0.1
a ka=0.03
a ka=0.1
a
Fa published value
b Fa=1 Fa published value
b Fa=1 Fa published value
b Fa=1 Fa published value
b Fa=1
ABCDEFGH
Cyclosporin A
c 1.46 1.86 2.38 3.68 2.07 2.96 4.16 7.15 3.21
Gemfibrozil 1.05 1.05 1.08 1.08 1.11 1.11 1.19 1.19 1.11
Fenofibrate –––––––– –
Lopinavir 1.76 1.76 2.56 2.56 2.74 2.74 4.58 4.58 2.91
Atazanavir 2.06 2.38 3.63 4.68 2.87 3.43 5.64 7.49 4.02
Amprenavir
d 1.19 1.21 1.49 1.54 1.34 1.37 1.87 1.95 1.49
aAbsorption rate constant obtained from (22,29)
bMaximum percentage absorbed or the oral availability as obtained from (22–25,29). For lopinavir, no data was available, hence Fa=1 was used
cCyclosporin A dose: 12.66 mg/kg/day for an individual with a weight of 70 kg
dImax and dose (used for the calculation of IIn,max), recalculated from Fosamprenavir data
Fig. 7 Comparison of reported AUC changes for atorvastatin (two
compounds) and rosuvastatin (six compounds) (27,37,43,51) with the
mean R-extrapolation values based on the inhibition curves obtained. The
percentage inhibition ± standard deviation in the OATP1B1 screening
assay is displayed as triangles. For fenofibrate, no IC50 value was obtained
in the investigated concentration interval, so no R-value could be
calculated. For the values used, see Tables I, II, and IV. The relative
changes in AUC for atorvastatin and rosuvastatin were taken from
(27,37,43,51) and from references therein.
Fig. 6 Variation in the range of calculated R-values (predicted change in
exposure) obtained by applying different equations (Eq. 2 using IC50 or
Eq. 3 using Ki), with different ka (0.03 or 0.1) and different Fa (literature
values (see Table IV)o r1 )( a). All R-values, as well as the corresponding
letter used, can be found in Table IV. The R calculation methods suggested
by the International Transporter Consortium (3) (B) and Hirano et al.( 22)
(H) are indicated here with black arrows. An overview of the R-values
calculated for each compound using the methods suggested by the
International Transporter Consortium (3) (B) with white bars and by
Hirano and coworkers (22) (H) with grey bars (b). The mean R-values
based on all eight values calculated (R-values A–H) for each compound are
shown as black bars.
422 Karlgren et al.similar in silico models, it is now possible to predict the
inhibition pattern of molecular structures within the
chemical space of drug-like molecules and to identify
specific and overlapping inhibitors (20). In 2005, Chang
and co-workers published a substrate pharmacophore for
OATP1B1 (40), which we also examined. However, neither
the pharmacophore nor the predictive quantitative model
approach that they adopted was successful in predicting our
inhibition data. The inability to generate these models with
our data was not surprising, given the larger size (n=146)
and higher structural diversity of our dataset in comparison
to that investigated by Chang et al.( n=19). We conclude
that the development of global pharmacophore models for
structurally diverse inhibitors will require structural infor-
mation about the binding site that is not currently available
for these integral membrane proteins.
Many groups have reported that statins, in particular,
interact with the OATP1B1 transporter e.g. (22,41,42), and
therefore this class of compounds was studied in further
detail in this paper. All of the statins investigated here were
identified as OATP1B1 inhibitors; the same was observed
for the seven protease inhibitors examined. This is in
agreement with the results available in the literature, where
the more polar statins, especially, have been reported to be
dependent on active uptake into the liver (mainly mediated
by OATPs) and where several clinical DDIs involving
statins and protease inhibitors have been described
(7,27,28,43).
In this investigation, we have further examined the
interaction potential and methods for in vivo prediction of
three protease inhibitors using atorvastatin as a substrate.
Atorvastatin was chosen since it is predominantly trans-
ported into hepatocytes by OATP1B1. Importantly, three
compounds were used for calibration (cf. (3)), cyclosporin A
(a strong OATP1B1 inhibitor increasing the plasma
concentration of atorvastatin and rosuvastatin in humans
by a factor of 10.5 and 7.1, respectively), gemfibrozil (a
moderate OATP1B1 inhibitor increasing the AUC for
atorvastatin and rosuvastatin by 1.2 and 1.9 times,
respectively), and fenofibate (a non-inhibitor in vivo of
rosuvastatin); for all changes in the AUC, see the review
of Kalliokoski (37) and references therein. Thus, the in vivo
ranking was comparable to the ranking observed here in
vitro, both for the IC50 values (Fig. 5a) and for the mean
predicted R-values (Fig. 7).
Our first question was whether the calculated R-values
could classify the chosen calibrators into interacting and
non-interacting drugs. In the recent paper by Giacomini
and co-workers, an R>2 was suggested as the threshold for
an in vivo interaction (3). As can be seen from Table V and
Fig. 6, this threshold should not be applied to all proposed
calculations of the R-value. However, for all predictions the
strong inhibitor cyclosporin A had a higher R-value than
the moderate inhibitor gemfibrozil. Hence, our conclusion
is that the R-values correctly classified the compounds into
interacting and non-interacting drugs, but that an R-value
of larger than 2 is not always applicable.
Our next question was if the R-values also could predict
the magnitude of the cyclosporin A/gemfibrozil-statin
interactions. A mean R-value of 3.21 was obtained for the
cyclosporin A-statin interaction and a larger R-value might
have been expected from the large effect on the AUC of
atorvastatin and rosuvastatin, respectively. However, cyclo-
sporin A is a multispecific inhibitor that interacts with
several transporters and metabolizing enzymes (including
cytochromes P450s that are responsible for statin metabolism)
(3,44,45) and therefore, the large effects of the two statins
caused by cyclosporin A are not only a reflection of the
OATP1B1 interaction, but of the overall effect on several
transporters and enzymes in vivo. For gemfibrozil the minor
change in predicted atorvastatin exposure (mean R-value of
1.11) is in agreement with the low increase in the AUC
observed for the gemfibrozil-atorvastatin interaction in
human studies (1.2-fold increase in AUC) (Fig. 7,T a b l eII)
(46). In addition, it is also in agreement with other in vitro–in
vivo extrapolations made previously (22). For gemfibrozil-
rosuvastatin interactions, a slightly larger AUC increase of
1.9-fold has been observed (see Table II). This difference is
probably the result of slightly different substrate/inhibition
profiles for the interacting drugs (47–49). In summary, this
shows that predicting the magnitude of interactions based on
R-values is more difficult than classifying compounds as
interacting or non-interacting. For more quantitative pre-
dictions the contribution of additional factors, such as drug
metabolizing enzymes and multiple transporters needs to be
considered.
To investigate to what extent it is possible to classify and
predict the magnitude of DDIs, the three test compounds
lopinavir, atazanavir and amprenavir were used. For these
compounds, limited clinical data is available regarding drug
transporters and transporter-mediated DDIs with atorvas-
tatin. Concomitant treatment with these compounds and
rosuvastatin resulted in increased rosuvastatin plasma
concentrations for lopinavir and atazanavir (with a 2.1
and 3.1-fold increase, respectively (27,43)) suggesting
involvement of transporter inhibition, most likely of
OATP1B1. For amprenavir no increase was observed in
the rosuvastatin plasma concentration (43). The R-values
for the three protease inhibitors suggest a more than 2-fold
change in the exposure of atorvastatin for patients
concomitantly treated with lopinavir (six out of eight R-
values >2) and atazanavir (all eight R-values >2), but not
amprenavir (all eight R-values <2) (Table IV, Fig. 7),
thereby correctly classifying these three compounds into
interacting/non-interacting drugs. The clinical data for
rosuvastatin-lopinavir or rosuvastatin-atazanavir DDIs
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reported changes in the AUC are within the range of the
predicted R-values and the average R-values are approxi-
mately 30% higher than the AUC-change. We conclude
that these three test compounds, too, could be correctly
classified as inhibitors/non-inhibitors using R calculations.
Several different values for the various parameters
required for the calculation of R-values have been
suggested. How does the R-value vary with different choices
of values? To investigate this issue, we calculated R-values
using eight different combinations of variables. Of these
eight R-values, the most pronounced difference between the
groups of non-inhibitors and inhibitors was observed for R-
value H (Table IV, Fig. 6a). Hence, according to our data,
this combination of values and method of calculation can
be considered as the most discriminating for the classification
of compounds. In addition, R-value H also gives the highest
R-values for all compounds analyzed and can therefore be
considered to represent a “worst case scenario” prediction. If
we take all five compounds into consideration, and disregard
potential interactions with other transporters or enzymes,
then R-value H (Table IV) will also be closer to the actual
change in the AUC for rosuvastatin. Surprisingly, using a
method favored elsewhere (3), give lower R-values and a
poorer separation between the groups of inhibitors and non-
inhibitors, as compared to R-value H. Besides the consider-
able impact of the variables selected and the method used for
the calculation, also different in vitro methods can affect the
obtained R-values. This becomes clear when comparing the
R-values obtained here for lopinavir with those calculated in
reference (3). In this case, the discrepancy in the R-values
(R-value B 1.76 vs 9.2) is solely dependent on the
differences in IC50 obtained in the various studies and cell
systems used. Hence, the possibility of the substrate,
concentration or in vitro system used having an impact on
the calculations cannot be excluded. Thus, calibration of the
range and threshold of the R-value in each experimental
system is a preferred approach.
In summary our results clearly stress the importance of
using the reference inhibitors derived from known and well-
defined clinical interactions as calibrators, and they under-
score the need for a thorough analysis of the extrapolation
method used instead of focusing on a proposed threshold
of, e.g., greater than two-fold change in exposure. By taking
these precautions, over or underestimations of possible
interactions are more likely to be avoided, and hence a
better prediction of the clinical situation ought to be
obtained. This reasoning is analogous to that applied in
other in vitro–in vivo predictions, such as in vivo absorption
predictions from Caco-2 cell monolayer permeability
experiments, where the use of reference drugs as calibrators
can account for large variations in the observed cut-off
values in different laboratories (50).
CONCLUSIONS
In this study, we identified 65 OATP1B1 inhibitors, of
which 22 had not been identified previously as interacting
with the OATP1B1 transporter. To our knowledge, this is
the most comprehensive investigation of OATP1B1 inhibi-
tion conducted to date, as well as the first global
computational classification model developed for the
prediction of inhibition of the OATP1B1 transporter.
Furthermore, we applied newly recommended in vitro–in
vivo extrapolation methods for the prediction of clinical
DDIs with transport proteins (3). Our classification of
OATP1B1 in vivo interactions was in good agreement with
reported clinical data and emphasizes the need to include
compounds whose clinical inhibition pattern is known to
calibrate the R-value. Awareness of how the different
variables influence calculation of the R-value is essential.
We believe that the results obtained in this work, together
with previous studies on hepatic transporter interactions,
will contribute to the ongoing discussion on the applications
and development of relevant predictive preclinical tools.
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